Merck's allergy business opens biopharmaceutical lab in Germany

Merck's allergy business opens biopharmaceutical lab in Germany

6:41 AM, 4th March 2017
Merck's allergy business opens biopharmaceutical lab in Germany
The picture from the opening ceremony (L-R) Reinbek's mayor Bjoern Warmer; Simon Sturge; Marco Linari, Allergopharma CEO; Belen Garijo, Merck executive board and CEO Healthcare; Torsten Albig, Minister President of the Schleswig-Holstein area; and Henning Goertz, district administrator.

REINBEK, GERMANY: Allergopharma GmbH & Co KG, the allergy business unit of Merck, has opened its new biopharmaceutical production plant in Reinbek, near Hamburg. Torsten Albig, Minister President of the Schleswig-Holstein region, recognised the €42 million investment as a local milestone for the pharmaceutical industry as a key industry for the future.

Allergopharma is a leading player in the allergen immunotherapy (AIT) of type I allergies, such as hay fever or allergic asthma. Allergopharma’s aspiration is to be a trusted partner in supporting patients with innovative compounds in the diagnosis and treatment of allergies.

This is underlined by the new cutting edge biopharmaceutical factory, which covers 6,000 square meters. The entire glass clean room, in which the company will manufacture its products for causal treatment, can be found on the 2,000-square meter ground floor of the building.

“Allergopharma has now been around for 48 years. Around 600 employees, 500 of which in Schleswig-Holstein, are working hard to improve the remedies available to people with allergies. The extension is a powerful declaration of commitment to this location. I am delighted that Allergopharma remains faithful to the state. You are creating more workplaces in a thriving region. The Stormarn district now has an unemployment rate of only 3.7 percent. That means virtually full employment, and Allergopharma has played a big part in achieving this,” said Torsten Albig.

‘‘By this €42 million investment Merck is supporting the Reinbek site in order to expand the allergies business on a global scale. The new production building is part of this global expansion, and will support our growing business in the allergy marketplace,” said Simon Sturge, chief operating officer at the healthcare business sector, Merck.

“From a technology point of view, the new biopharmaceutical production is a quantum leap. It means an increase in supply safety for patients, a further improvement of product quality and future innovations towards improving therapy,” added Marco Linari, CEO of Allergopharma.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Covestro to showcase composites for lightweight construction

LEVERKUSEN, GERMANY: Fibre composite materials are lightweight and highly robust. This combination of properties opens up a wide range of potential us ...

Read more
Researchers turn shrimps into biodegradable plastic

CAIRO, EGYPT: Researchers at Egypt's Nile University are developing a way to turn dried shrimp shells that would otherwise be thrown away into thin fi ...

Read more
Clariant showcases new home & personal care formulations

MUMBAI, INDIA: Clariant has showcased new innovative ingredients and formulations for the home & personal care industry recently in Mumbai, India. ...

Read more
BASF inaugurates new mobile emission catalysts site in India

CHENNAI, INDIA: BASF Catalysts India Private Limited (BASF Catalysts), a global division of BASF SE has inaugurated its new mobile emissions catalysts ...

Read more
Covestro to showcase polyurethane solutions for cosmetics

LEVERKUSEN, GERMANY: Covestro said that it will be showcasing innovative beauty solutions based on polyurethane raw materials of the Baycusan brand. B ...

Read more
Sketching sensors with new conducting polymer pen

EVANSTON, US: Two Northwestern Engineering graduate students are drawing circles around the competition. Daniel Hickox-Young and Luke Prestowitz devel ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X